OSCR
Oscar Health, Inc.
OSCR's fundamentals are strong: revenue grew 55% and its operating margin went from −1.9% to 5.4%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
XENE
Xenon Pharmaceuticals Inc.
There isn't enough reported data to score XENE yet.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
XENE Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Unavailable |
XENE's profitability is currently weak. There isn't enough data to rate its revenue, cash flow and balance sheet.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
XENE PE Valuation
XENE has no meaningful PE right now: it lost money over the past year.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
XENE Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong growth | |
| -- | |
| Limited | |
| Moderate |
Analysts expect XENE's revenue to grow, with its earnings and profitability holding steady.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over XENE on earnings quality, reporting a profit while its opponent remains loss making.
XENE Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$4.70 | -$0.82 |
| Q2 2026 | -$4.74 | -$1.20 |
| Q1 2026 | -$4.70 | -$1.48 |
| Q4 2025 | -$4.36 | -$1.35 |
| Q3 2025 | -$3.88 | -$1.05 |
| Q2 2025 | -$3.54 | -$0.79 |
| Q1 2025 | -$3.22 | -$0.50 |
| Q4 2024 | -$3.01 | -$0.28 |
XENE lost $4.70 per share over the past year, a bigger loss than the year before.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over XENE on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
XENE Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2022 | $132K | -98% |
| Q2 2022 | $536K | -76% |
| Q1 2022 | $8.8M | +101% |
| Q4 2021 | $3.7M | -27% |
| Q3 2021 | $8.1M | +24% |
| Q2 2021 | $2.2M | -83% |
| Q1 2021 | $4.4M | -38% |
| Q4 2020 | $5.2M | +55% |
XENE's revenue has slid since its 2020 peak: $0 last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q1 2025 | -970% | N/A |
| Q3 2022 | -28885% | -28693 points |
| Q2 2022 | -5656% | -4641 points |
| Q1 2022 | -198% | +170 points |
| Q4 2021 | -665% | -414 points |
| Q3 2021 | -192% | -44 points |
| Q2 2021 | -1014% | -1010 points |
| Q1 2021 | -368% | -255 points |
XENE's operating margin was −970% last quarter, down 305 points from the same quarter a year ago.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over XENE on cash generation, producing positive trailing cash flow while its opponent burns cash.
XENE Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$90.6M | -$18.6M |
| Q2 2026 | -$95.7M | -$31.3M |
| Q1 2026 | -$89M | -$27.3M |
| Q4 2025 | -$81.8M | -$26.6M |
| Q3 2025 | -$72M | -$20.3M |
| Q2 2025 | -$64.4M | -$30.2M |
| Q1 2025 | -$61.7M | -$18.3M |
| Q4 2024 | -$55.2M | -$19.6M |
XENE has burned cash in almost every quarter: −$357M over the past year, against −$253M the year before.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
XENE Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +156K shares |
| 1 year | +26% | +20.5M shares |
| 3 years | +51% | +33.8M shares |
| 5 years | +142% | +58.6M shares |
| Available history | +201% | +66.6M shares |
XENE has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
XENE Net Leverage
XENE's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
XENE Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 39.9 | Neutral |
| Stochastic | 17.7 | Oversold |
XENE's weekly RSI is 40 (neutral) and its Stochastic is 18 (oversold).
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
XENE PE vs Healthcare Sector
XENE has no meaningful PE right now: it lost money over the past year.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over XENE on trend strength, trading above more of its moving averages.
XENE Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $37.2 | 10% above |
| 20 week MA | $51.4 | 20% below |
| 50 week MA | $50.3 | 18% below |
| 100 week MA | $43.4 | 5.4% below |
| 200 week MA | $41.5 | 1.3% below |
XENE has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 1.3% below its 200-week average.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over XENE on returns for 2026, with the stronger performance.
XENE Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $13.4 | $15.3 | +14% |
| 2021 | $15.3 | $30.5 | +100% |
| 2022 | $30.5 | $38.1 | +25% |
| 2023 | $38.1 | $46.1 | +21% |
| 2024 | $46.1 | $38.8 | -16% |
| 2025 | $38.8 | $44.8 | +15% |
| 2026 YTD | $44.8 | $41.0 | -8.6% |
XENE has finished higher in five of the last six years. It's down 8.6% so far in 2026.